Accessibility Menu
Aspen Pharmacare logo

Aspen Pharmacare(OTC) APNHF

Market Cap$3.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+133%
5 Year-6%
1 Year+25%
1 Month+2%
$8.90
+0.00%
+0.00Today
Aspen Pharmacare last closing stock price
MetricPriceDate
Last closeUSD 8.902026-08-14
Aspen Pharmacare stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.3%USD 8.702026-07-31
1 month+2.25%USD 8.702026-06-29
3 month+2.25%USD 8.702026-05-05
Year to date+42.79%USD 6.232025-10-16
1 year+24.81%USD 7.132025-06-10
3 year+2.04%USD 8.722023-06-07
5 year-6.46%USD 9.512021-07-02
Since inception+132.94%USD 3.822008-05-12

Aspen Pharmacare Financials at a Glance

Market Cap

$3.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

ZAR 83.89B

Net Income (TTM)

ZAR 1.42B

EPS (TTM)

-$0.23

P/E Ratio

-37.92

Dividend

$0.12

Beta (Volatility)

0.11 (Low)

Price

$8.90

Volume

105

Open

$8.90

Previous Close

$8.90

Daily Range

$8.90 - $8.90

52-Week Range

$6.23 - $8.90

Estimated Earnings Date

Sep 2, 2026

APNHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aspen Pharmacare

Aspen Pharmacare Holdings Limited is a global leader in the development, production, and distribution of specialized pharmaceutical products. The company operates primarily in two divisions: Commercial Pharmaceuticals and Manufacturing, offering a diverse range of products across various therapeutic areas.

Products and Services
  • Specialized anesthetics, including general anesthetics and muscle relaxants
  • Injectable anticoagulants, focusing on low molecular weight heparins and Xa inhibitors
  • Branded consumer and prescription medications, such as Circadin and Maltofer
Growth Outlook
  • Recent quarterly revenue reached ZAR 16.96 billion, indicating strong market demand
  • Net income for the latest quarter was ZAR 1.46 billion, showcasing profitability
  • Positive cash flow from operations of ZAR 3.55 billion supports future investments
Financial Highlights
  • Trailing twelve-month revenue of ZAR 69.5 billion reflects consistent growth
  • Current ratio of 3.64 indicates strong liquidity position
  • Dividend yield of 1.47% offers attractive returns to shareholders
Aspen Pharmacare Holdings Limited has established itself as a significant player in the pharmaceutical industry, with a focus on specialized and generic drug manufacturing. The company's diverse product portfolio, which includes anesthetics and anticoagulants, positions it well to meet the growing global demand for healthcare solutions. Recent financial performance highlights a robust revenue stream and profitability, underscoring the company's operational efficiency and market strength. With a solid liquidity position and positive cash flow, Aspen is well-equipped to pursue future growth opportunities and enhance shareholder value.
AI Generated • Aug 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,557

CEO

Stephen Bradley Saad, PhD

Website

www.aspenpharma.com

Headquarters

Durban, NL 4321, ZA

APNHF Financials

Key Financial Metrics (TTM)

Gross Margin

41.91%

Operating Margin

16.01%

Net Income Margin

-5.19%

Return on Equity

-2.41%

Return on Capital

6.36%

Return on Assets

-1.56%

Earnings Yield

-2.64%

Dividend Yield

1.38%

Payout Ratio

-47.07%

Stock Overview

Market Cap

$3.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

444.02M

Volume

105

Avg. Volume

4.828

Financials (TTM)

Gross Profit

ZAR 36.63B

Operating Income

ZAR 9.65B

EBITDA

ZAR 12.57B

Operating Cash Flow

ZAR 12.43B

Capital Expenditure

-ZAR 5.32B

Free Cash Flow

ZAR 7.13B

Cash & ST Invst.

ZAR 5.58B

Total Debt

ZAR 32.72B

Aspen Pharmacare Performance Analysis

Aspen Pharmacare annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30ZAR 2,291,231,296-9.7%
20242024-06-30ZAR 2,388,834,3334.3%
20252025-06-30ZAR 2,387,723,936-0.0%
20262026-06-30ZAR 2,062,644,479-13.6%
Aspen Pharmacare sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3012.3%
Q22024-12-31-6.8%
Q42025-06-30-2.5%
Q22025-12-31-20.7%
Aspen Pharmacare annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30ZAR 0.66-29.6%
20242024-06-30ZAR 0.53-20.0%
20252025-06-30ZAR -0.13N/A
20262026-06-30ZAR 0.35N/A
Aspen Pharmacare sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-53.8%
Q22024-12-31128.9%
Q42025-06-30-245.4%
Q22025-12-31142.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

ZAR 16.96B

-19.1%

Gross Profit

ZAR 7.40B

-19.9%

Gross Margin

43.64%

N/A

Market Cap

$3.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$413.31K

N/A

Employees

9,557

N/A

Net Income

ZAR 1.46B

-36.3%

EBITDA

ZAR 4.04B

-22.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

ZAR 5.58B

-51.9%

Total Debt

ZAR 32.72B

-9.4%

Accounts Receivable

ZAR 10.07B

-19.8%

Inventory

ZAR 15.35B

-19.0%

Long Term Debt

ZAR 29.14B

+18.8%

Short Term Debt

ZAR 3.58B

-69.1%

Return on Assets

-1.56%

N/A

Return on Invested Capital

5.49%

N/A

Free Cash Flow

ZAR 2.43B

+714.4%

Operating Cash Flow

ZAR 3.55B

+45.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HYPMYHypera S.A.
$4.43+1.37%
CURLFCuraleaf Holdings, Inc.
$9.47-5.30%
MCRPFMicroPort Scientific Corporation
$0.85+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About APNHF

What is the current price of Aspen Pharmacare?

Aspen Pharmacare is trading at $8.90 per share.

What is the 52-week range for Aspen Pharmacare?

Over the past 52 weeks, Aspen Pharmacare has traded between $6.23 and $8.90.

How much debt does Aspen Pharmacare have?

As of the most recent reporting period, Aspen Pharmacare reported total debt of ZAR 949.91M.

How much cash does Aspen Pharmacare have on hand?

Aspen Pharmacare reported ZAR 976.08M in cash and cash equivalents in its most recent financial results.

What is Aspen Pharmacare’s dividend yield?

Aspen Pharmacare currently has a dividend yield of 1.38%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services